GlucoTrack (GCTK) Competitors $6.91 +0.25 (+3.75%) Closing price 04:00 PM EasternExtended Trading$6.95 +0.04 (+0.58%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GCTK vs. RVP, VVOS, NXL, COCH, XAIR, NXGL, IRIX, BTCY, FEMY, and HSDTShould you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include Retractable Technologies (RVP), Vivos Therapeutics (VVOS), Nexalin Technology (NXL), Envoy Medical (COCH), Beyond Air (XAIR), NexGel (NXGL), IRIDEX (IRIX), Biotricity (BTCY), Femasys (FEMY), and Solana (HSDT). These companies are all part of the "medical equipment" industry. GlucoTrack vs. Its Competitors Retractable Technologies Vivos Therapeutics Nexalin Technology Envoy Medical Beyond Air NexGel IRIDEX Biotricity Femasys Solana Retractable Technologies (NYSE:RVP) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk. Do institutionals & insiders hold more shares of RVP or GCTK? 7.6% of Retractable Technologies shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 57.1% of Retractable Technologies shares are held by company insiders. Comparatively, 0.7% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate RVP or GCTK? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is RVP or GCTK more profitable? GlucoTrack has a net margin of 0.00% compared to Retractable Technologies' net margin of -41.11%. GlucoTrack's return on equity of 0.00% beat Retractable Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Retractable Technologies-41.11% -17.15% -9.33% GlucoTrack N/A N/A -352.05% Which has higher earnings and valuation, RVP or GCTK? Retractable Technologies has higher revenue and earnings than GlucoTrack. Retractable Technologies is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRetractable Technologies$38.16M0.77-$7.01M-$0.29-3.38GlucoTrackN/AN/A-$22.60M-$56.60-0.12 Which has more volatility & risk, RVP or GCTK? Retractable Technologies has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, GlucoTrack has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Does the media prefer RVP or GCTK? In the previous week, Retractable Technologies had 2 more articles in the media than GlucoTrack. MarketBeat recorded 3 mentions for Retractable Technologies and 1 mentions for GlucoTrack. Retractable Technologies' average media sentiment score of 1.31 beat GlucoTrack's score of 1.00 indicating that Retractable Technologies is being referred to more favorably in the media. Company Overall Sentiment Retractable Technologies Positive GlucoTrack Positive SummaryRetractable Technologies beats GlucoTrack on 8 of the 13 factors compared between the two stocks. Get GlucoTrack News Delivered to You Automatically Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GCTK vs. The Competition Export to ExcelMetricGlucoTrackMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.22M$10.84B$6.17B$10.68BDividend YieldN/A1.88%5.72%4.83%P/E Ratio-0.1220.9129.4127.38Price / SalesN/A28.13588.00132.78Price / CashN/A25.1225.8230.35Price / Book-0.013.4912.496.68Net Income-$22.60M$208.83M$3.32B$276.27M7 Day Performance-10.14%0.68%2.38%0.95%1 Month Performance4.22%1.08%8.71%3.92%1 Year Performance-99.74%-8.29%61.90%36.33% GlucoTrack Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GCTKGlucoTrack0.5693 of 5 stars$6.91+3.8%N/A-99.7%$6.22MN/A-0.125Positive NewsShort Interest ↓RVPRetractable Technologies2.4861 of 5 stars$0.92-5.2%N/A+19.9%$27.46M$38.16M-1.70240Positive NewsShort Interest ↓Gap UpVVOSVivos Therapeutics1.5595 of 5 stars$3.18+0.3%$4.92+54.6%+8.6%$23.79M$15.03M-1.89160News CoverageNegative NewsShort Interest ↑NXLNexalin Technology2.6231 of 5 stars$1.29-3.7%$5.00+287.6%+20.6%$23.65M$174.81K-1.703Short Interest ↓COCHEnvoy Medical1.9906 of 5 stars$0.92+2.2%$9.50+934.5%-69.5%$21.39M$220K-0.6434XAIRBeyond Air4.3396 of 5 stars$2.70+2.7%$11.00+307.4%-64.9%$20.87M$3.70M-0.2370Short Interest ↓NXGLNexGel0.3266 of 5 stars$2.58+1.2%N/A-11.9%$20.57M$11.67M-6.4510IRIXIRIDEX0.4601 of 5 stars$1.06+1.4%N/A-36.6%$17.76M$48.67M-3.21120BTCYBiotricityN/A$0.65+6.2%N/A+137.0%$17.37M$12.06M-0.6040Gap DownFEMYFemasys2.8599 of 5 stars$0.59+10.7%$7.33+1,143.6%-45.9%$17.35M$1.89M-0.6930Gap DownHSDTSolana0.2687 of 5 stars$14.23-11.4%N/A-98.1%$17.31M$520K-0.0130Gap Down Related Companies and Tools Related Companies RVP Alternatives VVOS Alternatives NXL Alternatives COCH Alternatives XAIR Alternatives NXGL Alternatives IRIX Alternatives BTCY Alternatives FEMY Alternatives HSDT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GCTK) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
